NEW YORK – The Japanese Ministry of Health, Labor, and Welfare has approved AstraZeneca's and MSD's olaparib (Lynparza) for molecularly defined subsets of patients with advanced ovarian, prostate, and pancreatic cancers.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.